Results 231 to 240 of about 519,424 (350)

Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors [PDF]

, 2010
Yutaka Ueda, Tatsu Shimoyama, Haruyasu Murakami, Noboru Yamamoto, Yasuhide Yamada, Hitoshi Arioka, Tomohide Tamura   +6 more
openalex   +1 more source

Mutual Exclusion Analysis Shows that DUSP9 Negatively Regulates PD‐L1 Expression and Acts as a Target to Enhance Anti‐PD‐1 Efficacy

Advanced Science, EarlyView.
A mutually exclusive screening system is established to identify negative regulators of highly plastic genes. Dual specificity phosphatase (DUSP9) is a novel negative regulatory molecule of PD‐L1 by dephosphorylating STAT3, and acts as a target molecule in combination with PD‐1 antibody for tumor immunotherapy and a new clinical biomarker for ...
Yuzhe Hu, Ling Tang, Zheng Kuang, Danyi Huang, Ting Li, Gaofei Yin, Yingyu Chen, Wei Guo, Wenling Han, Pingzhang Wang   +9 more
wiley   +1 more source

Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. [PDF]

Blood Cancer J
Chohan KL, Gensini L, Seif S, Sun X, Feng L, Becnel MR, Gaballa MM, Lee HC, Pasvolsky O, Patel KK, Ye JC, Weber DM, Orlowski RZ, Thomas SK.   +13 more
europepmc   +1 more source

Figure 3 from Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen

Thomas Drabison, Mike Boeckman, Yan Yang, Kevin M. Huang, Peter de Bruijn, Mahesh R. Nepal, Josie A. Silvaroli, Anika T. Chowdhury, Eric D. Eisenmann, Xiaolin Cheng, Navjotsingh Pabla, Ron H.J. Mathijssen, Sharyn D. Baker, Shuiying Hu, Alex Sparreboom, Zahra Talebi   +15 more
openalex   +1 more source

IGF‐1 Deficiency Serves as an Integrated Biomarker Pathogenic Driver and Predictor in Poor Ovarian Response

Advanced Science, EarlyView.
IGF‐1 deficiency underlies poor ovarian response (POR), as reduced levels in follicular fluid and granulosa cells impair antral follicle formation and compromise reproductive outcomes. Including IGF‐1 as a biomarker significantly enhances the accuracy of models predicting both PORrisk and pregnancy success.
Zhu Hu, Yuanyuan Yu, Guanyou Huang, Jinnan Li, Chao Yang, Aizhuan Long, Jia Tang, Tengxiang Chen, Shuyun Zhao, Tuo Zhang   +9 more
wiley   +1 more source

PTPN9 dephosphorylates IGF1R^Y1165/1166 and alleviates IGF1R-mediated resistance to tyrosine kinase inhibitor in cholangiocarcinoma. [PDF]

J Exp Clin Cancer Res
Hu JM, Liu HQ, Zhang MH, Chen TL, Shi AD, Gao Q, Liu YJ, Wang X, Sun KY, Deng J, Xu YF, Pan C, Li KS, Zhang ZL.   +13 more
europepmc   +1 more source

Autocrine Netrin‐1 Signaling in Hepatic Stellate Cells Drives Liver Fibrosis and Diet‐Induced Metabolic Dysfunction‐Associated Steatohepatitis in Mice

Advanced Science, EarlyView.
Netrin‐1 expression is upregulated in hepatic stellate cells (HSCs) during metabolic dysfunction–associated steatohepatitis and injury‐mediated liver fibrosis. Secreted Netrin‐1 establishes an autocrine positive feedback loop by binding to UNC5B receptors on HSCs.
Jiahui Zhao, Yajie Peng, Hongyan Lei, Tianyi Wang, Huajuan Wang, Bo Wang, Jin Li, Xiaoying Li, Xuelian Xiong   +8 more
wiley   +1 more source

Targeting Microglial CD49a Inhibits Neuroinflammation and Demonstrates Therapeutic Potential for Parkinson's Disease

Advanced Science, EarlyView.
This study shows that integrin receptor CD49a (Itga1 gene) is significantly upregulated in hyperactivated microglia and microglia‐specific knockdown of Itga1 rescues neuroinflammation and neurodegeneration in a chronic Parkinson's disease (PD) model by targeting PGAM5‐mediated mitochondrial dysfunction and NLRP3 activation. Targeted inhibition of CD49a
Huanpeng Lu, Yunmin Zhu, Xi Wang, Zelin Wu, Zijian Xu, Rongqing Chen, Yanwu Guo   +6 more
wiley   +1 more source

Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers. [PDF]

Front Oncol
Kluitmans DJF, Melis JJTM, van den Bossche E, Ytsma J, de Roos JADM, van Linden OPJ, Grobben Y, Kooijman JJ, Zaman GJR.   +8 more
europepmc   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source